The Business Times
business-time-50

J&J drug unit to leverage Singapore's biotech hub

'Very lively biotech hub' spurs pharmaceutical arm's external collaborations

google-preferred-sourceAdd BT as a preferred source
Annabeth Leow

Annabeth Leow

Published Sun, Oct 28, 2018 · 09:50 PM

    Singapore

    JOHNSON & Johnson's (J&J) regional pharmaceutical head believes that Singapore offers innovation, research and development tie-up opportunities, even as wider insurance coverage in the Asia-Pacific is expected to fuel growth for drugmakers.

    Ong Ai Hua, the group chairman for Janssen Asia Pacific, the pharmaceutical arm of J&J, told The Business Times that "our focus in Singapore is on innovation - not so much on manufacturing".

    TRENDING NOW

    Leopold Aschenbrenner had no professional investing experience before launching Situational Awareness in 2024.  

    Rise and fall of Situational Awareness: How Leopold Aschenbrenner’s AI fund stumbled

    Online shopping has brought convenience and incredible range into the living room, allowing suppliers and brands to bypass department stores.

    From Yaohan and Galeries to Metro: The rise and fall of department stores in Singapore

    Frasers Tower in Cecil Street was valued at S$2.12 billion as at Sep 30, 2025. Only Frasers Property’s half stake is available for sale.

    More office buildings lined up for sale ahead of impending Marina One deal

    Grant Wee built Hideaway as a massage-and-bathhouse concept centred on solitude and recovery.

    UOB CEO’s youngest child Grant Wee turns burnout into a wellness business

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More